Genmab

Milestones as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Genmab: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 4 Oct 2026.

Clinical trials 30 in our ClinicalTrials.gov registers · 5 in the EU register

Showing 10 of 30, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 36 compounds

EU trials register (CTIS) 5 authorised or ongoing · 1 in Ireland

• A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer2025-524202-15-00 · Phase III · Authorised · site in Ireland
• A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers2025-524130-26-00 · Phase II · Ongoing
• A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy2024-519818-31-01 · Phase III · Ongoing
• A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer2025-522107-18-00 · Phase II · Ongoing
• A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)2025-522167-15-00 · Phase III · Ongoing

NICE technology appraisals 1 of its medicines · 1 current

• Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentNICE TA1164 · Recommended · 11 Jun 2026

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Genmab): founded 1998, headquarters Copenhagen, website genmab.com. Wikidata Q2076526 · Wikipedia. From Wikidata (CC0), matched by the group's Legal Entity Identifier.

How this is matched: register records are linked to this page by the organisation name they carry, here Genmab; Genmab A/S. Spot a wrong match? Tell us.

From the annual reports Genmab A/S files with the US Securities and Exchange Commission (20-F, IFRS), in USD as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.